You're using a free limited version of DrugPatentWatch: Upgrade for Complete Access

Last Updated: December 25, 2024

Details for Patent: 12,071,423


✉ Email this page to a colleague

« Back to Dashboard


Which drugs does patent 12,071,423 protect, and when does it expire?

Patent 12,071,423 protects REYVOW and is included in one NDA.

This patent has thirty-three patent family members in twenty-one countries.


Drugs Protected by US Patent 12,071,423

Applicant Tradename Generic Name Dosage NDA Approval Date TE Type RLD RS Patent No. Patent Expiration Product Substance Delist Req. Patented / Exclusive Use Submissiondate
Eli Lilly And Co REYVOW lasmiditan succinate TABLET;ORAL 211280-001 Jan 31, 2020 RX Yes No ⤷  Subscribe ⤷  Subscribe Y ⤷  Subscribe
Eli Lilly And Co REYVOW lasmiditan succinate TABLET;ORAL 211280-002 Jan 31, 2020 RX Yes Yes ⤷  Subscribe ⤷  Subscribe Y ⤷  Subscribe
>Applicant >Tradename >Generic Name >Dosage >NDA >Approval Date >TE >Type >RLD >RS >Patent No. >Patent Expiration >Product >Substance >Delist Req. >Patented / Exclusive Use >Submissiondate

International Family Members for US Patent 12,071,423

Country Patent Number Estimated Expiration Supplementary Protection Certificate SPC Country SPC Expiration
Argentina 119319 ⤷  Subscribe
Australia 2020310852 ⤷  Subscribe
Australia 2023201473 ⤷  Subscribe
Brazil 112021026219 ⤷  Subscribe
Canada 3146129 ⤷  Subscribe
>Country >Patent Number >Estimated Expiration >Supplementary Protection Certificate >SPC Country >SPC Expiration

Make Better Decisions: Try a trial or see plans & pricing

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.